Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Zynex stock (ZYXI)

Buy Zynex stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Zynex is a medical distribution business based in the US. Zynex shares (ZYXI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.32 – a decrease of 0.24% over the previous week. Zynex employs 1,100 staff and has a trailing 12-month revenue of around $193.7 million.

Our top picks for where to buy Zynex stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

How to buy Zynex stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ZYXI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Zynex stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Crypto alternative
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Zynex stock price (NASDAQ: ZYXI)

Use our graph to track the performance of ZYXI stocks over time.

Zynex shares at a glance

Information last updated 2024-11-27.
Latest market close$8.32
52-week range$7.15 - $13.77
50-day moving average $8.24
200-day moving average $9.78
Wall St. target price$17.50
PE ratio 59.6429
Dividend yield N/A
Earnings per share (TTM) $0.14

Is it a good time to buy Zynex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zynex price performance over time

Historical closes compared with the close of $8.32 from 2024-11-29

1 week (2024-11-26) -0.12%
1 month (2024-11-01) -5.02%
3 months (2024-09-03) 5.45%
6 months (2024-06-03) -15.53%
1 year (2023-12-01) -7.96%
2 years (2022-12-02) -39.71%
3 years (2021-12-03) 10.6653
5 years (2019-12-03) 9.6393

Is Zynex stock undervalued or overvalued?

Valuing Zynex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zynex's P/E ratio

Zynex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Zynex shares trade at around 60x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zynex's EBITDA

Zynex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.5 million.

The EBITDA is a measure of a Zynex's overall financial performance and is widely used to measure a its profitability.

Zynex financials

Revenue TTM $193.7 million
Operating margin TTM 7.61%
Gross profit TTM $126.5 million
Return on assets TTM 3.99%
Return on equity TTM 10.23%
Profit margin 2.49%
Book value $1.12
Market Capitalization $265.9 million

TTM: trailing 12 months

Zynex share dividends

We're not expecting Zynex to pay a dividend over the next 12 months.

Have Zynex's shares ever split?

Zynex's shares were split on a 11:10 basis on 4 January 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 11 shares. This wouldn't directly have changed the overall worth of your Zynex shares – just the quantity. However, indirectly, the new 9.1% lower share price could have impacted the market appetite for Zynex shares which in turn could have impacted Zynex's share price.

Zynex share price volatility

Over the last 12 months, Zynex's shares have ranged in value from as little as $7.15 up to $13.77. A popular way to gauge a stock's volatility is its "beta".

ZYXI.US volatility(beta: 0.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynex's is 0.535. This would suggest that Zynex's shares are less volatile than average (for this exchange).

Zynex overview

Zynex, Inc. , together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring.

Frequently asked questions

What percentage of Zynex is owned by insiders or institutions?
Currently 51.274% of Zynex shares are held by insiders and 28.01% by institutions.
How many people work for Zynex?
Latest data suggests 1,100 work at Zynex.
When does the fiscal year end for Zynex?
Zynex's fiscal year ends in December.
Where is Zynex based?
Zynex's address is: 9655 Maroon Circle, Englewood, CO, United States, 80112
What is Zynex's ISIN number?
Zynex's international securities identification number is: US98986M1036
What is Zynex's CUSIP number?
Zynex's Committee on Uniform Securities Identification Procedures number is: 98986M103

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site